#PubSaludMurcia Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. https://t.co/JI9oxyTDFx
RT @BibliotecaHUCA: PubMed- https://t.co/Oz8CYjLkrj Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinica…
RT @BibliotecaHUCA: PubMed- https://t.co/Oz8CYjLkrj Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinica…
PubMed- https://t.co/Oz8CYjLkrj Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. @HUCA_Asturias #publiHUCA @PaulaJFonseca #MedicalOncology @
RT @BVMurciasalud: #PubSaludMurcia Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a fea…
#PubSaludMurcia Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status https://t.co/0m6sV3sXqn